menu
    • menu
    [{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Bretisilocin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gilgamesh Pharmaceuticals","amount2":1.2,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":1.2,"dosageForm":"Undisclosed","sponsorNew":"Gilgamesh Pharmaceuticals \/ Abbvie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Gilgamesh Pharmaceuticals \/ Abbvie Inc"}]

    Find Clinical Drug Pipeline Developments & Deals for Bretisilocin

    Menu

    Bretisilocin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Gilgamesh Pharmaceuticals

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            Gilgamesh Pharmaceuticals

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bretisilocin

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : $1,200.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            AbbVie to Acquire Gilgamesh Bretisilocin, a Novel, Investigational Therapy

                            Details : AbbVie will GM-2505 (bretisilocin) acquire Gilgamesh's lead investigational candidate, currently in development for the treatment of patients with moderate-to-severe major depressive disorder.

                            Product Name : GM-2505

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 25, 2025

                            Lead Product(s) : Bretisilocin

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : $1,200.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth